Relmada Therapeutics (RLMD) Profit After Tax (2012 - 2026)
Relmada Therapeutics (RLMD) reported Profit After Tax of -$19.1 million for Q1 2026, down 8.5% year-over-year from -$20.8 million in Q1 2025, and up 4.11% on a QoQ basis from -$19.9 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Profit After Tax data on file, last reported at -$19.1 million in Q1 2026.
- Quarterly Profit After Tax fell 8.5% year-over-year to -$19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$58.9 million (up 22.23% YoY) and the FY2025 annual result came in at -$57.4 million, up 28.25% from the prior year.
- Profit After Tax advanced to -$19.1 million in Q1 2026 per RLMD's latest filing, from -$19.9 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$9.9 million in Q2 2025 and bottomed at -$39.9 million in Q2 2022.
- The 5-year median for Profit After Tax is -$21.8 million (2024), against an average of -$24.3 million.
- The widest annual swing landed in 2022, when Profit After Tax slumped 78.91%; it then soared 53.55% in 2025.
- Tracing RLMD's Profit After Tax over 5 years: stood at -$37.9 million in 2022, then jumped by 33.68% to -$25.2 million in 2023, then advanced by 25.86% to -$18.7 million in 2024, then dropped by 6.49% to -$19.9 million in 2025, then gained by 4.11% to -$19.1 million in 2026.
- Per Business Quant, the three latest RLMD Profit After Tax figures stand at -$19.1 million (Q1 2026), -$19.9 million (Q4 2025), and -$10.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -19.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.05 Mn |
| Dec 31, 2025 | -19.87 Mn |
| Sep 30, 2025 | -10.09 Mn |
| Jun 30, 2025 | -9.87 Mn |
| Mar 31, 2025 | -17.56 Mn |
| Dec 31, 2024 | -18.66 Mn |
| Sep 30, 2024 | -21.73 Mn |
| Jun 30, 2024 | -17.77 Mn |
| Mar 31, 2024 | -21.83 Mn |
| Dec 31, 2023 | -25.17 Mn |
| Sep 30, 2023 | -22.00 Mn |
| Jun 30, 2023 | -25.30 Mn |
| Mar 31, 2023 | -26.32 Mn |
| Dec 31, 2022 | -37.94 Mn |
| Sep 30, 2022 | -39.42 Mn |
| Jun 30, 2022 | -39.93 Mn |
| Mar 31, 2022 | -39.75 Mn |
| Dec 31, 2021 | -34.38 Mn |
| Sep 30, 2021 | -42.61 Mn |
| Jun 30, 2021 | -26.55 Mn |
| Mar 31, 2021 | -22.22 Mn |
| Dec 31, 2020 | -20.76 Mn |
| Sep 30, 2020 | -16.90 Mn |
| Jun 30, 2020 | -11.12 Mn |
| Mar 31, 2020 | -10.67 Mn |
| Dec 31, 2019 | -8.20 Mn |
| Sep 30, 2019 | -3.67 Mn |
| Jun 30, 2019 | -4.12 Mn |
| Mar 31, 2019 | -2.69 Mn |
| Dec 31, 2018 | -7.13 Mn |
| Sep 30, 2018 | -3.38 Mn |
| Mar 31, 2018 | -3.20 Mn |
| Dec 31, 2017 | -1.43 Mn |
| Sep 30, 2017 | -981,686.00 |
| Jun 30, 2017 | -1.63 Mn |
| Mar 31, 2017 | -1.98 Mn |
| Dec 31, 2016 | -1.03 Mn |
| Sep 30, 2016 | -1.64 Mn |
| Jun 30, 2016 | -3.32 Mn |
| Mar 31, 2016 | -1.86 Mn |
| Dec 31, 2015 | -2.46 Mn |
| Sep 30, 2015 | 4.66 Mn |
| Jun 30, 2015 | 6.04 Mn |
| Mar 31, 2015 | -2.46 Mn |
| Dec 31, 2014 | 5.46 Mn |
| Sep 30, 2014 | -29.84 Mn |
| Jun 30, 2014 | -21.34 Mn |
| Mar 31, 2014 | 6.49 Mn |
| Nov 30, 2013 | -14,374.00 |
| May 31, 2013 | -19,485.00 |
| Feb 28, 2013 | -4,146.00 |
| Nov 30, 2012 | -9,020.00 |
| Aug 31, 2012 | -8,629.00 |
| May 31, 2012 | -2,481.00 |